Last reviewed · How we verify
R2: Lenalidomide plus placebo maintenance
Lenalidomide is an immunomodulatory agent that enhances T-cell proliferation and NK cell activity while inhibiting TNF-α and IL-6 production, combined with placebo for maintenance therapy.
Lenalidomide is an immunomodulatory agent that enhances T-cell proliferation and NK cell activity while inhibiting TNF-α and IL-6 production, combined with placebo for maintenance therapy. Used for Multiple myeloma maintenance therapy (post-induction treatment).
At a glance
| Generic name | R2: Lenalidomide plus placebo maintenance |
|---|---|
| Also known as | Revlimid |
| Sponsor | University of Leeds |
| Drug class | Immunomodulatory agent (IMiD) |
| Target | Cereblon (CRBN) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Lenalidomide binds to cereblon (CRBN), a component of an E3 ubiquitin ligase complex, leading to selective degradation of IKZF1 and IKZF3 proteins. This results in enhanced immune cell activation and anti-tumor effects. In this R2 regimen (lenalidomide maintenance following induction therapy), the drug is used to sustain remission and delay disease progression.
Approved indications
- Multiple myeloma maintenance therapy (post-induction treatment)
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Fatigue
- Peripheral neuropathy
- Venous thromboembolism
Key clinical trials
- A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. (PHASE3)
- Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: